Skip to main content

Exploration of safety, tolerability and clinical efficacy of Solnatide IMP in patients infected with the 2019 new coronavirus

Project description

Testing new drug solnatide IMP in COVID-19 patients

Call for proposal

H2020-SC1-PHE-CORONAVIRUS-2020
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

RTDS - VEREIN ZUR FORDERUNG DER KOMMUNIKATION UND VERMITTLUNG VON FORSCHUNG, TECHNOLOGIE UND INNOVATION (RTDS VEREIN, ENGL. RTDS ASSOCIATION)
Address
Lerchengasse 25/2-3
1080 Wien
Austria
Activity type
Other
EU contribution
€ 132 228,75

Participants (4)

OPIS SRL
Italy
EU contribution
€ 365 833,34
Address
Via Matteotti 10
20832 Palazzo Aliprandi
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany
EU contribution
€ 150 000
Address
Geschwister Scholl Platz 1
80539 Muenchen
Activity type
Higher or Secondary Education Establishments
BCN PEPTIDES SA
Spain
EU contribution
€ 310 937,50
Address
Carretera Comarcal C-244 Km 22 Poligon Industrial Els Fogars Sector Ii
08777 Santa Quinti De Mediona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH
Austria
EU contribution
€ 667 025,41
Address
Mariahilferstrasse 136 Top 1.15
1150 Wien
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)